VRTX Vertex Pharmaceuticals
CF cash machine funding a real pipeline; the price already assumes success in kidney and pain.
The story
Vertex holds a near-monopoly in cystic fibrosis. Its CFTR modulators (Trikafta, and now Alyftrek with its lower royalty burden) produce franchise-level margins and patent protection into the late 2030s. The company is putting that cash into diversification: Casgevy for sickle cell and beta-thalassemia, Journavx for non-opioid pain, and povetacicept and inaxaplin in kidney disease. It is a mature cash machine trying to buy a second growth act, and execution on that pipeline will decide its value beyond CF.
I kept every driver unchanged because nothing material has moved since September. TTM revenue of 12.59B and a 40% operating margin track the path toward 45% as Alyftrek's royalty savings arrive and the 2024 IPR&D charge fades from the comparison. Ten percent growth fits the 10.4% five-year CAGR. The 12-year horizon reflects CF exclusivity plus the pipeline runway, and a 0.9 beta suits defensive, diversified rare-disease revenue.
Value drivers
| Revenue growth (Y1) | 10.0% |
| Terminal growth | 3.5% |
| Forecast horizon | 12y |
| Target operating margin | 45.0% |
| Years to target margin | 4 |
| Sales-to-capital | 1.50 |
| Beta | 0.90 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 9.1% |
| Terminal WACC | 9.5% |
Valuation bridge
| PV of explicit FCFF | 46.99B |
| PV of terminal value | 49.19B |
| Equity value | 99.24B |
| ÷ shares → per share | $391.53 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 13.85B | 10.0% | 41.3% | 4.87B | 839.15M | 4.03B | 3.69B |
| 2 | 15.15B | 9.4% | 42.5% | 5.49B | 868.52M | 4.62B | 3.88B |
| 3 | 16.48B | 8.8% | 43.8% | 6.14B | 890.56M | 5.25B | 4.05B |
| 4 | 17.84B | 8.2% | 45.0% | 6.84B | 904.15M | 5.93B | 4.19B |
| 5 | 19.20B | 7.6% | 45.0% | 7.36B | 908.26M | 6.45B | 4.17B |
| 6 | 20.56B | 7.0% | 45.0% | 7.88B | 901.97M | 6.97B | 4.14B |
| 7 | 21.88B | 6.5% | 45.0% | 8.38B | 884.54M | 7.50B | 4.08B |
| 8 | 23.17B | 5.9% | 45.0% | 8.88B | 855.42M | 8.02B | 4.00B |
| 9 | 24.39B | 5.3% | 45.0% | 9.34B | 814.32M | 8.53B | 3.90B |
| 10 | 25.53B | 4.7% | 45.0% | 9.78B | 761.19M | 9.02B | 3.78B |
| 11 | 26.57B | 4.1% | 45.0% | 10.18B | 696.25M | 9.48B | 3.64B |
| 12 | 27.50B | 3.5% | 45.0% | 10.54B | 620.05M | 9.92B | 3.49B |
Key risks
- Journavx and Casgevy ramps stay slow, so revenue remains concentrated in CF
- Kidney readouts for povetacicept and inaxaplin disappoint, or competitors such as Otsuka's sibeprenlimab erode the IgAN opportunity
- Drug pricing pressure from MFN and IRA policy, or a CF competitor, compresses the 45% margin
Catalysts
- Povetacicept IgAN accelerated approval and launch trajectory
- Journavx uptake data and Phase 3 results in diabetic peripheral neuropathy pain